Pharma sector outlook: ICRA pegs 7-9% revenue growth for FY26, US headwinds cloud prospects
Pharma sector outlook: ICRA pegs 7-9% revenue growth for FY26, US headwinds cloud prospects
India's pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, operating profit margins are expected to remain resilient. Companies are increasing R&D spending and capital expenditure, focusing on speciality products.
India's pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, operating profit margins are expected to remain resilient. Companies are increasing R&D spending and capital expenditure, focusing on speciality products.
India's pharmaceutical sector is poised for strong revenue growth, projecting 7-9% in FY26, driven by domestic and European demand. While US market growth may moderate, operating profit margins are expected to remain resilient. Companies are increasing R&D spending and capital expenditure, focusing on speciality products. 
